This course is designed to convey a broad-based understanding of fundamental principles pertaining to the toxicology of drugs and environmental agents and their adverse actions on living systems. The course is divided into three units that will examine: 1) basic principles of pharmacology and toxicology including dose-response, structure-activity relationships, toxicokinetics and toxicodynamics, and biotransformation of xenobiotic compounds, 2) target organ toxicity and mechanisms of disease, and 3) non-target organ toxicity including toxicogenomics, mutagenesis and carcinogenesis, as well as an introduction to clinical and forensic toxicology.
BMS 300 (Principles of Human Physiology) or BMS 360 (Fundamentals of Physiologoy); CHEM 341 (Organic Modern Chemistry I) or CHEM 344 (Modern Organic Chemistry Laboratory). BC 401 (Comprehensive Biochemistry I) or BC 403 (Comprehensive Biochemistry II).
Textbooks and Materials
Textbooks and materials can be purchased at the CSU Bookstore unless otherwise indicated.
- Casarett & Doull's Toxicology: The Basic Science of Poisons*, 8th Ed.
Klaassen, Curtis D.
*Hard copy or e-book is acceptable.
Dr. Tjalkens is Professor of Toxicology and Neuroscience in the Department of Environmental and Radiological Health Sciences at Colorado State University. He earned his Ph.D. in Toxicology from the University of Colorado Medical Center in 1998 and completed a postdoctoral fellowship in Neurotoxicology and Experimental Neuropathology at the University of Michigan in 2001. He was an Assistant Professor at Texas A&M University from 2001 – 2004 before joining the faculty of Colorado State University, where he attained the rank of Professor in 2013. Dr. Tjalkens’ research focuses on gene-environment interactions in neurodegenerative diseases, with particular emphasis on Parkinson’s disease. Specific areas of research include the molecular pathogenesis of neuroinflammatory brain injury and the role of neuroinflammation in the progression of Parkinson’s disease. Projects are also investigating new molecular targets for therapeutic approaches to mitigate neuroinflammation.